<DOC>
	<DOCNO>NCT01648582</DOCNO>
	<brief_summary>The purpose study examine once-weekly dulaglutide efficient safe compare once-daily insulin glargine participant type 2 diabetes mellitus inadequate glycemic control 1 2 oral antihyperglycemic medication ( OAM ) ( metformin and/or sulfonylurea ) , addition healthy lifestyle change recommend healthcare provider .</brief_summary>
	<brief_title>A Study Comparing Effects Safety Dulaglutide With Insulin Glargine Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Have type 2 diabetes mellitus least 6 month Have take metformin and/or sulfonylurea least 3 month screen stable therapeutic dose least 8 week Glycosylated hemoglobin ( HbA1c ) value ≥7.0 % ≤11.0 % Adult men adult nonpregnant , nonbreastfeeding woman Body Mass Index ( BMI ) ≥19.0 ≤35.0 kilograms/square meter ( kg/m^2 ) Stable weight ( ±5 % ) ≥3 month prior screen Have type 1 diabetes mellitus Have previous treatment glucagonlike peptide1 ( GLP1 ) receptor agonist , GLP1 analog , incretin mimetic Have treatment dipeptidyl peptidaseIV ( DPPIV ) inhibitor , alphaglucosidase inhibitor ( AGI ) , thiazolidinedione ( TZD ) , glinide Have gastric empty abnormality Have cardiac disorder define unstable angina , myocardial infarction , coronary artery bypass graft surgery , percutaneous coronary intervention , heart failure , arrhythmia , transient ischemic attack , stroke Have poorly control hypertension ( systolic blood pressure 160 millimeter mercury [ mmHg ] diastolic blood pressure 95 mmHg ) Have impair liver function Have impair kidney function Have history chronic pancreatitis acute pancreatitis Have serum calcitonin ≥20 picograms per milliliter ( pg/mL ) Have personal family history medullary Ccell hyperplasia , focal hyperplasia , carcinoma , multiple endocrine neoplasia type 2 ( MEN 2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>